Comparison of anti-HBs persistence after hepatitis B vaccination on two-dose schedule and three-dose schedule among adults: results from a 12-year follow up study in China. Issue 5 (4th May 2019)

• Record Type: Journal Article
• Authors: Lu, Jingjing; Yan, Bingyu; Liu, Jiaye; Wu, Wenlong; Feng, Yi; Xu, Aiqiang; Zhang, Li
• Is Part Of: Human vaccines & immunotherapeutics. Volume 15:Issue 5(2019)
• Page Start: 1171
• Page End: 1176
• Publication Date: 2019-05-04
• Subjects: Anti-HBs persistence -- hepatitis B vaccination -- immunization schedule -- adults; Vaccines -- Periodicals; 615.372
• DOI: 10.1080/21645515.2018.1554972
• Languages: English
• ISSNs: 2164-5515

Abstract

ABSTRACT: Comparison of anti-HBs persistence after hepatitis B vaccination on two-dose schedule and three-dose schedule among adults is still controversial. In this study, adults were followed up at 12 years after the primary immunization. Three hundred and forty-one and 288 adults with age 15 through 40 years old were given anti-HBV vaccination on a 0-, 1-, and 6-month schedule or on a 0- and 6-month one, respectively (in 2003). Blood samples of 202 patients on 0-, 1- and 6-month schedule and 194 patients on 0- and 6-month regimen were collected at one month and twelve years (in 2015) after the primary series and anti-HBs levels were measured. The seroprotection rate for 3-dose schedule and 2-dose one was 71.78% (95% CI = 65.04%, 77.87%) and 53.61% (95% CI = 46.07%, 60.49%). The GMC of anti-HBs was 31 mIU/mL (95% CI = 24, 41) and 12 mIU/mL (95% CI = 9, 17), respectively. Participants using three doses had higher seroprotection rate and GMC (P < 0.001). Multivariable analysis showed that subjects with anti-HBs titers ≥100 mIU/ml just after the primary series had a higher probability of anti-HBs levels than <10 mIU/ml and 10–100 mIU/ml at follow-up (OR = 8.36, 95% CI : 3.41–20.49, P < 0.001; OR = 43.28, 95% CI : 11.45–163.51, P < 0.001; β = 0.77, 95% CI : 0.48–1.06, P < 0.001; β = 1.20, 95% CI : 0.86 ~ 1.54, P < 0.001). In conclusions, adults receiving HepB primary immunization on 0-, 1- and 6-month schedule might have more prolonged anti-HBs than those on 0-, 6-month schedule, although good anti-HBs persistence could be achieved after HepB immunization on both schedules.